ClinicalTrials.gg
RecruitingNCT06508775LONGSAFEUpdated Oct 9, 2026

Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies

An interventional study of MB-CART19.1 and MB-CART20.1 in Melanoma Stage III, B-cell Non Hodgkin Lymphoma and Pediatric ALL, sponsored by Miltenyi Biomedicine GmbH. Recruiting at 7 sites in Germany. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Miltenyi Biomedicine GmbH · Not applicable, Interventional, and Other

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 284 studies in Melanoma with a site in Germany — 37 open to participants now, 71 under way, 20 of them phase 3. Melanoma · Germany.

Planned enrollment
186th of 249
40 · median 162
Started
2024
with 12 others
No phase
16 of 284
8 open now
Primary completion
2040-12
later than 70 of 70 live
Registered
263rd of 284
by date

Among the 284 studies in Melanoma with a site in Germany, this one is the 186th largest by planned enrollment of the 249 interventional ones that give a count, is one of 13 that started in 2024, is one of 16 with no phase, reaches primary completion later than 70 of the 70 other live ones, and was the 263rd registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

37 of the 284 studies in Melanoma with a site in Germany are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 284 studies in Melanoma with a site in Germany, or all of them as a file.
02

Study summary

The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.

Read the detailed description

The focus in this trial is on the occurrence of any late adverse reactions (AR), serious adverse events (SAE), serious adverse reactions (SAR) and adverse events of special interest (AESI), i.e. relapse or progression of the underlying disease, life-threatening infections, death due to any case, new and secondary malignancies, lymphocyte counts, detection of the transgene of the CAR T cells, detection of replication-competent lentivirus (RCL), developmental tracking in pediatric patients and furthermore, assessment of the primary status of disease progression and overall survival.

03

Conditions studied

  • Melanoma Stage III
  • B-cell Non Hodgkin Lymphoma
  • Pediatric ALL
  • Childhood Non-Hodgkin Lymphoma
  • Acute Lymphatic Leukemia
  • Chronic Lymphatic Leukemia
  • Melanoma Stage IV
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient underwent treatment with a Miltenyi CAR T cell therapy in one of the parent trials at least 12 months prior to enrollment in long-term follow-up.
  • Patient has provided prior to enrollment.

Exclusion criteria

Exclusion Criteria:

  • No exclusion criteria
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Long-term follow-up of CAR T cell therapy

    Assessment of long-term safety and efficacy of Miltenyi CAR T treatment.

    Biological: MB-CART19.1 · Biological: MB-CART20.1 · Biological: MB-CART2019.1

Interventions

  • BiologicalMB-CART19.1

    Assessment of long-term safety and efficacy of MB-CART19.1 treatment.

    Also known as: CD19-targeting CAR T cells, Anti-CD19 CAR T cells

  • BiologicalMB-CART20.1

    Assessment of long-term safety and efficacy of MB-CART20.1 treatment.

    Also known as: CD20-targeting CAR T cells, Anti-CD20 CAR T cells

  • BiologicalMB-CART2019.1

    Assessment of long-term safety and efficacy of MB-CART2019.1 treatment.

    Also known as: CD20/CD19-targeting CAR T cells, Anti-CD20/CD19 CAR T cells

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Percentage of patients with late-onset adverse reactions (AR), serious adverse events (SAE), serious adverse reactions (SAR) and adverse events of special interest (AESI) including relapse or progression of the underlying disease, life-threatening infections, death due to any cause, new and secondary malignancies

    Time frame: through study completion, up to 14 years

Secondary outcomes

  1. Lymphocyte count

    B and T lymphocyte count

    Time frame: through study completion, up to 14 years

  2. Height

    Height

    Time frame: through study completion, up to 14 years

  3. Weight

    Weight

    Time frame: through study completion, up to 14 years

  4. Tanner staging for pediatric patients

    Tanner staging for pediatric patients

    Time frame: through study completion, up to 14 years

  5. Menstruation status for pediatric patients

    Did the patient experience their first menstrual cycle (menarche)? If yes, enter date

    Time frame: through study completion, up to 14 years

  6. RCL

    Percentage of patients with detectable replication-competent lentivirus (RCL) (if results of 2 consecutive years are negative for an individual patient, further sampling will not be continued for this patient; if results of all samples in first year of primary trial were negative for an individual patient, sampling will not be continued for this patient in this long-term follow-up trial)

    Time frame: through study completion, up to 14 years

  7. Relapse / Progression

    Percentage of patients who relapse or progress since enrollment and rate of surviving patients

    Time frame: through study completion, up to 14 years

  8. Detectable Transgene levels

    Percentage of patients with detectable transgene levels (if results of 2 consecutive years are negative for an individual patient, further sampling will be stopped for this patient)

    Time frame: through study completion, up to 14 years

07

Study locations

2 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2040, 199 months after the start.

Of 227 interventional studies with no phase under Melanoma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 199 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2024
First posted
Jul 18, 2024
StartActual
May 5, 2024
Primary completionEst.
Dec 31, 2040
CompletionEst.
Dec 31, 2040
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06508775
Lead sponsor
Miltenyi Biomedicine GmbH
Responsible party
Sponsor
First posted
Jul 18, 2024
Start date
May 5, 2024
Primary completion
Dec 31, 2040 (estimated)
Completion
Dec 31, 2040 (estimated)
Last update
Oct 9, 2026

Study contacts

Clinical Trial Manager
Contact
clinicaltrials.gov@miltenyi.com
+4922048306820
Claudia Rössig, Prof. Dr.
principal investigator · Universitätsklinikum Münster

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1 · Autologous Anti-CD20 CAR Transduced CD4/CD8 Enriched T-cells MB-CART20.1 · Zamtocabtagene autoleucel

Start the discussion